Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
23.75
Dollar change
-0.26
Percentage change
-1.08
%
IndexRUT P/E- EPS (ttm)-0.38 Insider Own0.76% Shs Outstand164.65M Perf Week-8.30%
Market Cap3.91B Forward P/E17.09 EPS next Y1.39 Insider Trans-7.15% Shs Float163.51M Perf Month-9.14%
Income-61.29M PEG- EPS next Q0.06 Inst Own97.11% Short Float5.76% Perf Quarter6.60%
Sales726.44M P/S5.39 EPS this Y271.35% Inst Trans0.91% Short Ratio4.81 Perf Half Y-12.10%
Book/sh2.62 P/B9.06 EPS next Y119.16% ROA-9.17% Short Interest9.42M Perf Year17.05%
Cash/sh2.66 P/C8.92 EPS next 5Y- ROE-14.73% 52W Range17.71 - 33.99 Perf YTD-24.15%
Dividend Est.- P/FCF235.03 EPS past 5Y28.03% ROI-12.78% 52W High-30.13% Beta0.40
Dividend TTM- Quick Ratio2.28 Sales past 5Y27.73% Gross Margin94.27% 52W Low34.11% ATR (14)1.14
Dividend Ex-Date- Current Ratio2.42 EPS Y/Y TTM71.78% Oper. Margin-10.10% RSI (14)38.78 Volatility5.10% 4.02%
Employees598 Debt/Eq0.13 Sales Y/Y TTM40.45% Profit Margin-8.44% Recom1.71 Target Price33.50
Option/ShortYes / Yes LT Debt/Eq0.11 EPS Q/Q206.75% Payout- Rel Volume0.69 Prev Close24.01
Sales Surprise3.24% EPS Surprise-3.08% Sales Q/Q69.27% EarningsFeb 27 AMC Avg Volume1.96M Price23.75
SMA20-5.78% SMA50-13.55% SMA200-7.19% Trades Volume1,357,521 Change-1.08%
Date Action Analyst Rating Change Price Target Change
Jan-30-24Initiated Robert W. Baird Outperform $40
Jan-24-24Upgrade Needham Hold → Buy $37
Dec-19-23Upgrade Morgan Stanley Equal-Weight → Overweight $31 → $40
Dec-14-23Downgrade Deutsche Bank Buy → Hold $25
Dec-13-23Initiated Citigroup Buy $38
Dec-12-23Initiated Deutsche Bank Buy $25
Nov-06-23Upgrade Mizuho Neutral → Buy $20 → $35
Oct-17-23Initiated UBS Buy $33
Oct-10-23Upgrade JP Morgan Neutral → Overweight $29 → $32
Jan-03-23Upgrade Guggenheim Neutral → Buy $22
Feb-29-24 09:05AM
08:44AM
Feb-28-24 04:05PM
09:12AM
Feb-27-24 05:20PM
04:56PM Loading…
04:56PM
04:27PM
04:05PM
Feb-22-24 08:16PM
Feb-21-24 04:05PM
Feb-20-24 10:00AM
Feb-13-24 04:05PM
Feb-08-24 01:15PM
Jan-30-24 08:48PM
05:00PM
05:31PM Loading…
Jan-26-24 05:31PM
Jan-25-24 08:42AM
Jan-19-24 04:05PM
Jan-18-24 04:05PM
Jan-12-24 05:02PM
Dec-21-23 04:05PM
Dec-18-23 04:05PM
Dec-13-23 09:24PM
04:14PM
01:41PM
Nov-30-23 09:05AM
Nov-27-23 09:05AM
Nov-21-23 11:03PM
05:00PM
Nov-17-23 09:40AM
08:42AM Loading…
Nov-16-23 08:42AM
Nov-14-23 04:12PM
Nov-08-23 05:24PM
Nov-04-23 01:10PM
Nov-02-23 06:51PM
04:37PM
04:05PM
Oct-31-23 04:05PM
Oct-26-23 10:02AM
Oct-23-23 09:05AM
Oct-19-23 04:05PM
Oct-18-23 05:00PM
Oct-10-23 10:49AM
09:32AM
Oct-07-23 05:01AM
Sep-30-23 10:30AM
Sep-22-23 06:23PM
Sep-19-23 04:05PM
Aug-30-23 04:05PM
Aug-28-23 06:00PM
Aug-22-23 08:30AM
Aug-19-23 10:44AM
Aug-14-23 04:05PM
Aug-04-23 12:36PM
Aug-02-23 04:26PM
04:05PM
Aug-01-23 07:30PM
Jul-25-23 11:21AM
Jul-24-23 04:05PM
Jul-21-23 09:40AM
Jul-19-23 04:04PM
Jul-15-23 08:19AM
Jul-14-23 04:04PM
11:41AM
Jul-13-23 07:11PM
04:05PM
Jun-26-23 05:00PM
Jun-13-23 04:05PM
Jun-12-23 01:24PM
Jun-08-23 11:10AM
Jun-07-23 11:30AM
05:58AM
Jun-01-23 09:04AM
May-08-23 05:25PM
04:13PM
04:05PM
09:21AM
May-05-23 04:04PM
May-02-23 09:04AM
Apr-25-23 09:04AM
Apr-20-23 09:04AM
Apr-17-23 09:04AM
Apr-11-23 09:04AM
07:44AM
Mar-13-23 12:56PM
12:11PM
Mar-10-23 09:45PM
Mar-07-23 09:45AM
Mar-02-23 05:45AM
Mar-01-23 05:41AM
Feb-28-23 04:00PM
09:26AM
Feb-27-23 05:25PM
04:05PM
Feb-20-23 10:00AM
Feb-14-23 04:05PM
Feb-13-23 04:15PM
Jan-09-23 09:00AM
Jan-03-23 11:58AM
09:00AM
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAVIS STEPHENCEOFeb 26Sale24.675,577137,585101,890Feb 27 06:02 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERFeb 26Sale24.6777219,04521,067Feb 27 06:13 PM
Teehan BrendanEVP, COO, HEAD OF COMMERCIALFeb 26Sale24.6762415,39431,432Feb 27 06:10 PM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERFeb 26Sale24.6747411,69411,391Feb 27 06:07 PM
DAVIS STEPHENCEOJan 08Sale29.963,732111,81196,521Jan 09 06:00 PM
Teehan BrendanEVP, COO, Head of CommercialJan 08Sale29.9673121,90130,949Jan 09 06:00 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryJan 08Sale29.9659017,67646,901Jan 09 06:00 PM
Kihara JamesPrincipal Accounting OfficerDec 15Sale28.302,00056,60011,025Dec 15 07:37 PM
Schneyer Mark C.EVP, Chief Financial OfficerNov 20Sale22.645,108115,64520,486Nov 21 06:00 PM
Teehan BrendanEVP, COO, Head of CommercialNov 20Sale22.644,960112,29430,393Nov 21 06:00 PM
Kihara JamesPrincipal Accounting OfficerNov 20Sale22.641,98544,94013,025Nov 21 06:00 PM
DAVIS STEPHENCEOOct 06Sale21.9651,5631,132,32389,131Oct 06 09:59 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryOct 06Sale21.9616,369359,46345,857Oct 06 10:00 PM
Kihara JamesPrincipal Accounting OfficerSep 15Sale25.882,00051,76010,778Sep 19 06:31 PM
Schneyer Mark C.EVP, Chief Financial OfficerAug 21Sale29.0010,000289,97015,682Aug 23 07:31 PM
DAVIS STEPHENCEOJul 14Option Exercise20.77100,0002,077,000136,695Jul 18 06:00 PM
DAVIS STEPHENCEOJul 14Sale30.04100,0003,004,35036,695Jul 18 06:00 PM
DAVIS STEPHENCEOJul 12Sale25.0555,1041,380,44936,695Jul 13 08:27 PM
DAVIS STEPHENCEOJul 11Sale25.0016,498412,45091,799Jul 13 08:27 PM
Kihara JamesPrincipal Accounting OfficerJun 15Sale24.152,00048,3009,144Jun 16 04:38 PM
Brege LauraDirectorJun 12Sale24.874,500111,90613,502Jun 14 05:14 PM
Schneyer Mark C.EVP, Chief Financial OfficerJun 08Option Exercise0.001,893023,798Jun 12 08:48 PM
Schneyer Mark C.EVP, Chief Financial OfficerJun 08Sale25.0297424,36922,824Jun 12 08:48 PM
BAKER BROS. ADVISORS LPDirectorMay 24Buy25.48553,26314,096,82539,317,673May 24 05:09 PM
BAKER BROS. ADVISORS LPDirectorMay 23Option Exercise17.0125,000425,25038,620,261May 24 05:09 PM
BAKER BROS. ADVISORS LPDirectorMay 23Buy25.41209,0535,312,45838,811,515May 24 05:09 PM
BAKER BROS. ADVISORS LPDirectorMay 22Buy24.57134,2063,297,81538,607,761May 24 05:09 PM
Schneyer Mark C.EVP, Chief Financial OfficerMay 17Sale22.5015,310344,47521,905May 19 06:48 PM
Teehan BrendanEVP, COO, Head of CommercialMay 17Sale22.5014,869334,55224,356May 19 06:43 PM
Kihara JamesPrincipal Accounting OfficerMay 17Sale22.505,947133,80811,144May 19 06:54 PM
DAVIS STEPHENCEOMay 01Sale21.187,806165,331108,297May 02 07:02 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryMay 01Sale21.1891719,42225,513May 02 07:06 PM
Teehan BrendanEVP, COO, Head of CommercialMay 01Sale21.1854811,6079,487May 02 07:04 PM
Teehan BrendanEVP, COO, Head of CommercialApr 29Option Exercise0.001,567010,035May 02 07:04 PM
DAVIS STEPHENCEOApr 29Option Exercise0.0015,6250116,103May 02 07:02 PM
Kihara JamesPrincipal Accounting OfficerApr 10Sale18.145239,4875,197Apr 11 09:15 PM
DAVIS STEPHENCEOApr 06Sale18.168,582155,849100,478Apr 07 08:34 PM
Schneyer Mark C.EVP, Chief Financial OfficerApr 06Sale18.161,91634,7957,477Apr 07 08:37 PM
Teehan BrendanEVP, COO, Head of CommercialApr 06Sale18.161,75131,7988,468Apr 07 08:44 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryApr 06Sale18.161,45626,44123,425Apr 07 08:32 PM
Kihara JamesPrincipal Accounting OfficerApr 06Sale18.1670112,7304,231Apr 07 08:41 PM